Hardman & Co Research: Tissue Regenix (TRX): Credit facilities expand cash runway to 2021

Hardman & Co Research: Tissue Regenix (TRX): Credit facilities expand cash runway to 2021

WKN: A1C0FE ISIN: GB00B5SGVL29 Tissue Regenix Group PLC

0,07 USD
0,00 USD 0,00 %
26.06.2019 - 17:20
20.06.2019 15:22:02

Hardman & Co Research
Hardman & Co Research: Tissue Regenix (TRX): Credit facilities expand cash runway to 2021

20-Jun-2019 / 14:22 GMT/BST


Hardman & Co Research: Credit facilities expand cash runway to 2021

Tissue Regenix (TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for repair of soft tissue (dCELL) and bone (BioRinse). Following the acquisition of CellRight in the US in 2017, TRX embarked on a revised commercialisation strategy, which is clearly gaining traction. Sales grew 47% in 2018, reflecting strong demand, particularly for DermaPure in the US. To support further business expansion, including investment in facilities and working capital, credit facilities of up to $20m/£16m have been secured. Please click here for the full report:

https://www.hardmanandco.com/research/corporate-research/credit-facilities-expand-cash-runway-to-2021/

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH
www.hardmanandco.com
Follow us on Twitter @HardmanandCo
Contacts:

Dorothea Hill

+44 20 7194 7628


dmh@hardmanandco.com
 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

828109  20-Jun-2019 

fncls.ssp?fn=show_t_gif&application_id=828109&application_name=news&site_id=smarthouse

Aktien in diesem Artikel

Tissue Regenix Group PLC 0,07 0,00% Tissue Regenix Group PLC

Aktienempfehlungen zu Tissue Regenix Group PLC

  • Alle
  • Buy
  • Hold
  • Sell

Nachrichten

  • Nachrichten zu Aktien
  • Alle Nachrichten
pagehit